Component

LipoCol Forte red yeast rice preparation studied in 2012

Context-specific entity; species, compartment and exposure are stated on each claim.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. In 14 volunteers, single doses of one, two or four LipoCol Forte capsules produced dose-related lovastatin and lovastatin-acid exposure; one capsule twice daily for five days produced no significant accumulation.

    LipoCol Forte red yeast rice preparation studied in 2012 → Human plasma exposure to lovastatin hydroxy acid source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary full text PMC3513969
    experimental_model
    Human fed-state dose and repeat-dose study; 600 mg per capsule.
    limitations
    Does not establish identical kinetics for other formulations, chronic use or interacting-drug conditions.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The measured product had a defined short-term exposure profile.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 148–154

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human fed-state dose and repeat-dose study; 600 mg per capsule. · source_derived_draft · unverified_draft

    ## red-yeast-rice-lipocol-dose-response The measured product had a defined short-term exposure profile. In 14 volunteers, single doses of one, two or four LipoCol Forte capsules produced dose-related lovastatin and lovastatin-acid exposure; one capsule twice daily for five days produced no significant accumulation. Model: Human fed-state dose and repeat-dose study; 600 mg per capsule. Limitations: Does not establish identical kinetics for other formulations, chronic use or interacting-drug conditions. Evidence access: Primary full text PMC3513969 [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

  2. One 600 mg LipoCol Forte capsule did not significantly change the measured pharmacokinetics of 5 mg nifedipine in 14 volunteers.

    LipoCol Forte red yeast rice preparation studied in 2012 → Human nifedipine plasma exposure source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969
    experimental_model
    Human fasted-state single-dose pharmacokinetic comparison.
    limitations
    A null result for this dose does not exclude other drugs, preparations or exposures.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The predicted enzyme interaction was not demonstrated in this tested regimen.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 156–162

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human fasted-state single-dose pharmacokinetic comparison. · source_derived_draft · unverified_draft

    ## red-yeast-rice-nifedipine-null The predicted enzyme interaction was not demonstrated in this tested regimen. One 600 mg LipoCol Forte capsule did not significantly change the measured pharmacokinetics of 5 mg nifedipine in 14 volunteers. Model: Human fasted-state single-dose pharmacokinetic comparison. Limitations: A null result for this dose does not exclude other drugs, preparations or exposures. Evidence access: Primary full text PMC3513969 [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. Gemfibrozil 600 mg twice daily increased lovastatin-acid peak concentration and exposure area after LipoCol Forte in 13 volunteers.

    Gemfibrozil → Human plasma exposure to lovastatin hydroxy acid source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary full text PMC3513969
    experimental_model
    Human short-course gemfibrozil followed by one LipoCol Forte capsule.
    limitations
    The trial did not establish a unique responsible transporter or enzyme, nor measure a muscle-injury incidence.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    A coadministered drug increased exposure to the active acid.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 164–170

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human short-course gemfibrozil followed by one LipoCol Forte capsule. · source_derived_draft · unverified_draft

    ## red-yeast-rice-gemfibrozil-acid A coadministered drug increased exposure to the active acid. Gemfibrozil 600 mg twice daily increased lovastatin-acid peak concentration and exposure area after LipoCol Forte in 13 volunteers. Model: Human short-course gemfibrozil followed by one LipoCol Forte capsule. Limitations: The trial did not establish a unique responsible transporter or enzyme, nor measure a muscle-injury incidence. Evidence access: Primary full text PMC3513969 [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

  2. Gemfibrozil did not significantly change parent lovastatin pharmacokinetic parameters in that LipoCol Forte experiment.

    Gemfibrozil → Human plasma exposure to lovastatin source_derived_draftungraded
    Experimental context and source evidence
    evidence_access
    Primary full text PMC3513969
    experimental_model
    Same 13 volunteers and dosing protocol.
    limitations
    The positive acid result must not be generalized to every measured chemical form.
    nutrient_topic
    Red yeast rice collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · Red yeast rice
    plain_language
    The lactone and acid did not show the same interaction result.
    primary_references
    [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043

    Red yeast rice: constituents, mevalonate, CoQ and product-specific interactions (2026-09-20) · lines 172–178

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Same 13 volunteers and dosing protocol. · source_derived_draft · unverified_draft

    ## red-yeast-rice-gemfibrozil-lactone-null The lactone and acid did not show the same interaction result. Gemfibrozil did not significantly change parent lovastatin pharmacokinetic parameters in that LipoCol Forte experiment. Model: Same 13 volunteers and dosing protocol. Limitations: The positive acid result must not be generalized to every measured chemical form. Evidence access: Primary full text PMC3513969 [23227093] Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of Lovastatin. · 2012 · https://pubmed.ncbi.nlm.nih.gov/23227093/ · DOI 10.1155/2012/127043
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards